首页>
外国专利>
A method for detection of CYFRA21-1 Autoantibody-Antigen complex , CYFRA21-1 antigen and Lung Cancer diagnosis kit by using ratio of these markers
A method for detection of CYFRA21-1 Autoantibody-Antigen complex , CYFRA21-1 antigen and Lung Cancer diagnosis kit by using ratio of these markers
When cancer occurs, the quantitative change in the blood of most cancer-related antigens (tumor markers) is very small until the cancer stage 0 to 3, and the quantitative difference appears only at stage 4, so the quantitative change is low only by testing using only microscopic antigens. Because of the specificity and sensitivity (89% specificity, 43% sensitivity), it is not easy to distinguish between normal and cancer. In particular, in the early stages of cancer, stage 0~1, it is not possible to distinguish between normal and cancer. On the other hand, autoantibodies that specifically respond to cancer-related antigens show the greatest increase in volume at the early stage of cancer (stage 0~1), and show an increase of 5 to 10 times more than normal. The present invention relates to a lung cancer diagnosis method using the ratio of the anti-CYFRA21-1 autoantibody-antigen conjugate and the CYFRA21-1 antigen in a biological sample, and detects the anti-CYFRA21-1 autoantibody-antigen conjugate and the CYFRA21-1 antigen. It relates to a diagnostic kit and a detection method. The present invention is a method for diagnosing cancer of stage 0-1 using the ratio of the autoantibody-antigen conjugate and antigen in the blood of normal and cancer patients. The present invention provides a method for diagnosing lung cancer in stage 0-1 using the ratio of the anti-CYFRA21-1 autoantibody-antigen conjugate and the CYFRA21-1 antigen in the blood of normal and lung cancer patients. The present invention is the first in the world to provide a diagnostic kit and method of use for diagnosing the onset of stage 0-1 lung cancer with a specificity of 90% and a sensitivity of 76% using a non-invasive biological sample such as blood and plasma. We provide a kit and a method of use to diagnose lung cancer with a sensitivity of 60%. Since the diagnostic method of the present invention uses blood that is relatively easy to collect, unlike conventional diagnostic methods such as biopsy or CT, it is possible to diagnose stage 0-1 lung cancer very simply without burdening the patient. Because of its high accuracy and sensitivity, it can be usefully used in the diagnosis of lung cancer.
展开▼
